Withings ECG-Monitor Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

650 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-15

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the performance of Withings WBS08 with embedded Withings ECG Monitor in the automatic detection of atrial fibrillation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Validation of the Withings ECG Monitor for the Detection of Atrial Fibrillation

NCT05266235

Atrial Fibrillation

COMPLETED NA

Withings ECG-app Study

NCT05316350

Atrial Fibrillation

COMPLETED NA

Validation Study of a Watch for the Detection of Atrial Fibrillation

NCT04041466

Atrial Fibrillation Arrythmia, Cardiac

COMPLETED NA

WIBOFA - Validation of SCT02 With ECG-App for Detection of AF

NCT06351761

Atrial Fibrillation

RECRUITING NA

Validation Study of the Watch HWA09 and Its Softwares ECG-SW1 and PPG-SW1 for the Detection of Atrial Fibrillation

NCT04351386

Atrial Fibrillation Arrythmia, Cardiac

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atrial fibrillation

Group Type EXPERIMENTAL

Electrocardiogram recording

Intervention Type DEVICE

ECG recording with investigational device

Electrocardiogram recording

Intervention Type DEVICE

ECG recording with reference device

Normal Sinus Rhythm

Group Type EXPERIMENTAL

Electrocardiogram recording

Intervention Type DEVICE

ECG recording with investigational device

Electrocardiogram recording

Intervention Type DEVICE

ECG recording with reference device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electrocardiogram recording

ECG recording with investigational device

Intervention Type DEVICE

Electrocardiogram recording

ECG recording with reference device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female who are 22 years of age or older,
* Subject able to read, understand, and provide written informed consent,
* Subject willing and able to participate in the study procedures as described in the consent form,
* Subject able to communicate effectively with and willing to follow instructions from the study staff.

Exclusion Criteria

* Vulnerable subject with regard to regulations in force

* Subject who is deprived of liberty by judicial, medical or administrative decision,
* Underage subject,
* Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form.
* Subject within several of the above categories,
* Subject who refused to participate in the study,
* Subject mentally impaired resulting in limited ability to cooperate
* Subject with electrical stimulation by pacemaker
* Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)
* Patient unable to stay in an upright position for the duration of study measures
* Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)
* Acute pulmonary embolism or pulmonary infarction, within 90 days of screening
* Stroke or transient ischemic attack within 90 days of screening
* Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).
* History of life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)
* Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis over electrode attachment sites
* Known sensitivity to medical adhesives, isopropyl alcohol, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands
* Weight more than 180 kg

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No